Breast Cancer and Ovarian Tissue Cryopreservation: SWOT Analysis
Authors:
- Diego RaimondoDiego Raimondo
- Marisol DoglioliMDMarisol Doglioli
- Cristian ForastiereCFCristian Forastiere
- Rossella VicentiRVRossella Vicenti
- Marco SchirripaMSMarco Schirripa
- Enrico PazzagliaEPEnrico Pazzaglia
- Michele MisciaMMMichele Miscia
- Daniele NeolaDNDaniele Neola
- Linda BertoldoLBLinda Bertoldo
- Maria MassucciMMMaria Massucci
- Margherita SerraMSMargherita Serra
- Luigi CobellisLCLuigi Cobellis
Open Access
- 25 May 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4083
Abstract
Background/Objectives: Breast cancer is the most common malignancy in young women, many of whom face fertility impairment due to gonadotoxic treatments and prolonged endocrine therapy. Ovarian tissue cryopreservation (OTC) has emerged as an alternative fertility preservation (FP) strategy, particularly when controlled ovarian stimulation is not feasible. This study aimed to evaluate the role of OTC in breast cancer patients, with the aim of clarifying its current clinical role and future perspectives within fertility preservation counselling for this population. Methods: A structured SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis was conducted based on the current literature, addressing clinical efficacy, safety, and applicability of OTC in breast cancer patients. Results: Key strengths of OTC include the absence of delay in cancer treatment and the potential to restore both endocrine and reproductive function. However, limitations include the need for surgery, the theoretical risk of reintroducing malignant cells, and variable, less predictable reproductive outcomes compared with gamete-based strategies. Opportunities lie in advances in cryopreservation, transplantation techniques, and integration with in vitro maturation. Major threats include limited data in breast cancer-specific populations, challenges in BRCA mutation carriers, and low utilization rates affecting cost-effectiveness and healthcare sustainability. Conclusions: OTC represents a valuable complementary FP option for selected breast cancer patients, particularly in urgent settings. Despite promising outcomes, its use should remain individualized within multidisciplinary counseling, considering patient-specific oncological and reproductive factors, while further research is needed to clarify long-term safety and efficacy.Keywords
This publication has 54 references indexed in Scilit:
- Fertility Preservation in People With CancerJAMA, 2026
- Long-Term Locoregional Outcomes in a Contemporary Cohort of Young Women With Breast CancerJAMA Surgery, 2025
- Enhancement of angiogenesis and follicular survival using growth factors during ovarian tissue transplantation: a systematic reviewArchives of Gynecology and Obstetrics, 2025
- Impact of low versus high oxygen tension on human oocyte maturation during biphasic capacitation IVM (CAPA-IVM)Journal of Assisted Reproduction and Genetics, 2025
- A Geospatial Analysis of Disparities in Access to Oncofertility ServicesJAMA Oncology, 2023
- Perspectives on the development and future of oocyte IVM in clinical practiceJournal of Assisted Reproduction and Genetics, 2021
- Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservationArchives of Gynecology and Obstetrics, 2017
- Safety of fertility preservation in breast cancer patients in a register-based matched cohort studyBreast Cancer Research and Treatment, 2017
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Breast cancer incidence trends in European women aged 20–39 years at diagnosisBreast Cancer Research and Treatment, 2012